1. Home
  2. VERU vs AGPU Comparison

VERU vs AGPU Comparison

Compare VERU & AGPU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.27

Market Cap

40.9M

Sector

Health Care

ML Signal

HOLD

AGPU

Axe Compute Inc. Common Stock

N/A

Current Price

$6.54

Market Cap

36.8M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
VERU
AGPU
Founded
1971
2002
Country
United States
United States
Employees
N/A
14
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.9M
36.8M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
VERU
AGPU
Price
$2.27
$6.54
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$22.50
N/A
AVG Volume (30 Days)
59.8K
358.9K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$16,296,958.00
N/A
Revenue This Year
N/A
$12,476.23
Revenue Next Year
N/A
$55.17
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.36
$1.03
52 Week High
$4.59
$10.86

Technical Indicators

Market Signals
Indicator
VERU
AGPU
Relative Strength Index (RSI) 54.76 56.08
Support Level $2.12 $4.54
Resistance Level $2.67 $6.65
Average True Range (ATR) 0.12 0.84
MACD 0.02 0.01
Stochastic Oscillator 77.14 73.84

Price Performance

Historical Comparison
VERU
AGPU

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

About AGPU Axe Compute Inc. Common Stock

Axe Compute Inc functions as an active infrastructure operator. The company intends to expand access to AI compute resources by utilizing the Aethir network, which provides scalable, cost-efficient cloud GPU services for AI, machine learning, gaming, and rendering applications. Through the use of Aethir's decentralized international infrastructure, the company aims to provide access to bare-metal GPUs at scale for both emerging and established organizations.

Share on Social Networks: